ONCOHealthcare · Biotechnology

ONCO Stock Forecast: Onconetix, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$0.65

−2.68% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 14 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap

$2.6M

Ticker Nerd rank

14 / 100

Median analyst target

—

Analysts covering

Total return, dividends reinvested

−20.0%

−27.1%

YTD

−99.2%

−99.5%

From 52W high

−99.7%

From 52W low

0.0%

$206

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

ONCO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Onconetix, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

14 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Issuance

Accruals

Growth

Revisions

Volatility

Quality

Momentum

Value

Size (99): Smaller than most of the companies we track.

Value (1): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ONCO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ONCO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
13 Sept 2023	Maxim Group	Downgrade	Hold	—
26 Apr 2023	HC Wainwright & Co.	Maintains	Buy	—
1 Feb 2023	HC Wainwright & Co.	Reiterates	Buy	—
9 Dec 2022	HC Wainwright & Co.	Initiates	Buy	—
8 Dec 2022	Maxim Group	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ONCO appears on the weeks it earns a place.

Estimates

ONCO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Onconetix, Inc. (ONCO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 0.0×
Price / sales: 4.0×
Price / book: 0.2×
EV / EBITDA: 0.4×

Growth & margins

Revenue growth (YoY): −83.9%
Earnings growth (YoY): −78.9%
Gross margin: −7.7%
Operating margin: −13112.1%
Net margin: 77.6%

Returns & dividend

Return on equity: −105.2%
Return on assets: −27.0%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ONCO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
ONCOOnconetix, Inc.	$2.6M	14
CMNDClearmind Medicine, Inc.	$2.6M	8
VRAXVirax Biolabs Group Ltd.	$2.5M	13
VBIOValion Bio, Inc.	$2.7M	2
OGENOragenics, Inc.	$2.3M	10
MTNBMatinas BioPharma Holdings, Inc.	$2.9M	46
CDTCDT Equity, Inc.	$2.3M	15

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Onconetix, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ONCO news & analysis

Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series

GlobeNewsWire · 6 Aug 2026positive

Realbotix, the target of Onconetix's pending acquisition, entered into an agreement with a streaming platform to feature one of its humanoid robots as a robotic character in an upcoming episode of a popular Emmy-award-winning television series. Onconetix recently signed a definitive agreement to acquire Realbotix LLC, a subsidiary of Realbotix Corp.

Why it matters — ONCO watchers would care because the agreement reflects real-world adoption of humanoid robotics technology across education, healthcare, hospitality, and customer engagement, relating to the company's pending acquisition of Realbotix.

Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG

GlobeNewsWire · 5 Aug 2026positive

Onconetix, Inc. announced that its fully-owned Swiss subsidiary, Proteomedix AG, appointed co-founder and Proclarix co-developer Ralph Schiess, PhD to the PMX Board of Directors. The appointment was approved at the PMX Annual General Meeting on June 22, 2026, where Thomas Meier, PhD was re-elected Chairman for an additional one-year term.

Why it matters — The appointment brings a co-founder and Proclarix co-developer back to the board of Onconetix's Swiss subsidiary, adding relevant expertise at the subsidiary level.

FAQ

Frequently asked questions about ONCO stock

How does Ticker Nerd's model rank ONCO?

As at 22 Aug 2026, Onconetix, Inc. ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).

What is the ONCO stock forecast for 2030?

No analyst covering Onconetix, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ONCO are extrapolating price history, which says nothing about the business.

How has ONCO stock performed over the past year?

Onconetix, Inc. returned -99.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Onconetix, Inc. do?

What is the latest news on ONCO?

The most recent item we track (GlobeNewsWire, 6 Aug 2026): "Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series". Realbotix, the target of Onconetix's pending acquisition, entered into an agreement with a streaming platform to feature one of its humanoid robots as a robotic character in an upcoming episode of a popular Emmy-award-winning television series. Onconetix recently signed a definitive agreement to acquire Realbotix LLC, a subsidiary of Realbotix Corp.

Company

About Onconetix, Inc.

Onconetix Inc. is a commercial stage biotechnology company focused on the research, development, and commercialization of proprietary therapeutics, diagnostics, and services for oncology and men's health. It offers Entadfi, an FDA-approved once-daily oral pill combining finasteride and tadalafil for treating benign prostatic hyperplasia, a common prostate disorder. The company also provides Proclarix, an advanced in vitro protein-based blood diagnostic test designed for screening and diagnosing prostate cancer in men with indeterminate Prostate Specific Antigen levels. These products serve clinicians and patients by addressing key needs in prostate health and oncology, including treatment and early detection. Onconetix Inc. pursues partnerships, such as with LabCorp for Proclarix commercialization, to expand access in the United States, European Union, and other markets. Founded in 2018 and headquartered in Cincinnati, Ohio, Onconetix Inc. plays a role in advancing targeted solutions within the biotechnology sector.

CEO Ms. Karina M. Fedasz · 2 employees · United States · https://www.onconetix.com